KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial.

J Bedke, M S van der Heijden, G Sonpavde, M D Galsky, W Liao, L Shi, S I Blum, S Mitra, M Y Patel, T Powles

ESMO Open 11(3) 106089

PMID41747587
PMCIDPMC12955679
DOI10.1016/j.esmoop.2026.106089
发表日期2026-02-26
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:生活质量量表图;Figure 2:生活质量量表图;Figure 3:生活质量量表图。
摘要

摘要

BACKGROUND: In the phase III CheckMate 901 trial, nivolumab plus standard-of-care gemcitabine-cisplatin chemotherapy followed by nivolumab monotherapy significantly prolonged overall survival and progression-free survival versus gemcitabine-cisplatin alone in cisplatin-eligible patients with unresectable or metastatic urothelial carcinoma (UC). Here, using patient-reported outcome (PRO) data from CheckMate 901, we report effects of adding nivolumab to gemcitabine-cisplatin on health-related quality of life (HRQoL). PATIENTS AND METHODS: PRO assessments [European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and EuroQol 5-Dimension 5-Level (EQ-5D-5L)] were scheduled for both arms through the first 6 months of treatment (combination phase), and for the nivolumab plus gemcitabine-cisplatin arm thereafter (monotherapy phase). The prespecified primary PRO scale of interest was QLQ-C30 global health status/quality of life (QoL). Secondary scales of interest included QLQ-C30 physical functioning, role functioning, and fatigue, and the EQ-5D-5L visual analog scale. Noninferiority analysis involved a mixed-effect model for repeated measures to estimate differences in least-squares mean changes from baseline to week 16. The proportions of patients with meaningful changes were calculated using prespecified thresholds. RESULTS: In total, 524 patients were analyzed (nivolumab plus gemcitabine-cisplatin, n = 276; gemcitabine-cisplatin alone, n = 248). Overall least-squares mean changes through week 16 indicated the noninferiority of nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for global health status/QoL and all secondary scales. At week 16, the proportions of patients with meaningful changes in global health status/QoL (improvement, 29.2% versus 23.0%; deterioration, 28.3% versus 30.4%) and all secondary PRO scales were similar in both arms. CONCLUSIONS: Adding nivolumab to gemcitabine-cisplatin did not worsen HRQoL compared with gemcitabine-cisplatin alone in the first 16 weeks of therapy. These findings support nivolumab plus gemcitabine-cisplatin as standard first-line therapy for cisplatin-eligible patients with unresectable or metastatic UC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Completion rates by visit and treatment (all randomized population). Completion rates are shown for all patients expected for PRO assessment for (A) EORTC QLQ-C30, (B) EQ-5D-5L utility index, and (C) EQ-5D-5L VAS. Data are shown up to the last visit with n ≥ 10. EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire—Core 30; EQ-5D-5L, EuroQol 5-Dimension 5-Level; GC, gemcitabine–cisplatin; NIVO, nivolumab; PRO, patient-reported outcome; VAS, visual analog scale.
非 KM Figure
Figure 2Figure 2 Overall LS mean changes up to week 16 (primary and secondary PRO scales). For each PRO scale, either the lower (QLQ-C30 global health status/QoL, physical functioning, role functioning, and the EQ-VAS) or the upper (QLQ-C30 fatigue) bound of the 95% CI for the difference in least square means is bolded for comparison with the respective noninferiority margin.CI, confidence interval; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire—Core 30; EQ-5D-5L, EuroQol 5-Dimension 5-Level; GC, gemcitabine–cisplatin; LS, least squares; NIVO, nivolumab; PRO, patient-reported outcome; QoL, quality of life; VAS, visual analog scale. a Noninferiority was defined by the lower bound of the minimum important difference for EORTC QLQ-C30 scales; and by the lower bound of the range of estimates for EQ-5D-3L by Pickard et al. for EQ-VAS.
非 KM Figure
Figure 3Figure 3 Observed mean changes from baseline in primary and secondary PRO scales by visit and treatment (PRO-assessable population). Observed mean changes from baseline are shown for the EORTC QLQ-C30 scales of (A) global health status/QoL (primary scale), (B) physical functioning (secondary scale), (C) role functioning (secondary scale), (D) fatigue (secondary scale), and (E) the EQ-5D-5L VAS (secondary scale). Data are shown up to the last visit with n ≥ 10. CI, confidence interval; GC, gemcitabine–cisplatin; NIVO, nivolumab; PRO, patient-reported outcome; QoL, quality of life; VAS, visual analog scale.
非 KM Figure